InhaleRx Advances Phase 2 Trial for Non-Opioid Cancer Pain Treatment

InhaleRx Limited ( (AU:IRX) ) has provided an announcement.

InhaleRx Limited has announced the execution of a Study Order with iNGENū CRO Pty Ltd for a Phase 2 clinical trial of its non-opioid inhaled treatment, IRX-211, for Breakthrough Cancer Pain (BTcP). This trial, fully funded by Clendon Biotech Capital, aims to evaluate the efficacy, safety, and tolerability of IRX-211, addressing the urgent need for fast-acting pain relief alternatives to opioids. The study represents a significant milestone for InhaleRx in providing effective therapies for cancer patients and highlights the company’s commitment to addressing critical unmet medical needs in pain management.

More about InhaleRx Limited

InhaleRx Limited is an Australian drug development company focused on creating unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors. The company aims to achieve U.S. FDA approval and registration through rapid and cost-effective regulatory pathways, such as 505(b)(2). Its primary medical indications under investigation include Breakthrough Cancer Pain (BTcP) and Panic Disorder (PD), both of which have limited safe and effective treatment options.

Average Trading Volume: 117,606

Technical Sentiment Consensus Rating: Sell

Current Market Cap: A$8.54M

For detailed information about IRX stock, go to TipRanks’ Stock Analysis page.